The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. NASH and type 2 diabetes, as well as for a number of cancers.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

APRIL 7, 2021

Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory ,” said Hudson. Leveraging R&D efforts to address crucial treatment gaps. The company is also committed to ecodesigning all its new products by 2025.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”

Disease 52

Disease FDA Therapies Trials 52

New Drug Approvals

JANUARY 31, 2024

The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.

Therapies 52

Therapies Disease FDA Trials 52

The Pharma Data

MAY 15, 2023

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule Teva Pharmaceutical Industries Ltd. Teva is one of the world’s largest manufacturer of generic medicines, making treatments more affordable and accessible.

Government 40

Government Pharmaceuticals Compliance Production 40

Drug Target Review

OCTOBER 1, 2024

Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Moreover, increasing treatment complexity will require more sophisticated scientific exchange.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030. billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Dr. Stephen McLeod, M.D.,

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

Vial

MAY 20, 2024

In the field of clinical research , this pipeline can be broken down into several stages and processes specifically designed to rigorously validate the safety and efficacy of new drugs and treatments. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

FEBRUARY 24, 2022

with more than 8 million cases expected by 2030. with preserved ejection fraction, a form of heart failure that has very limited treatment options.” vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

MARCH 11, 2021

And at Pharmaceuticals, we are seeing success in our late-stage pipeline and are very well positioned with the investments we are making in our future. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. through 2023.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

The Pharma Data

AUGUST 5, 2021

percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

MAY 4, 2021

This donation furthers both Lilly and Direct Relief’s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. Baricitinib has not been approved for the treatment of COVID-19, but has been authorized for emergency use by the FDA.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030). Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. from 2024 to 2030. These services range from clinical study design and data management to statistical analysis and regulatory support.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

NOVEMBER 5, 2020

Regeneron Pharmaceuticals, Inc. Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” FDA approved Inmazeb for Ebola ( Zaire ebolavirus). Oncology Program.

Production 40

Production Trials FDA FDA Approval 40

The Pharma Data

FEBRUARY 8, 2021

Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. percentage points to 27.1%.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Fabrazyme ® was launched in China in May and is the first treatment for Fabry disease approved in China. percentage points to 27.1%.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

APRIL 27, 2021

Pharmaceuticals. First-quarter 2021 Pharmaceutical sales increased 3.8% Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. reflecting lower treatment compliance during the COVID-19 pandemic.

Vaccine 52

Vaccine Production FDA Disease 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. An example: For GSPR 12 on devices that incorporate medicinal products, rather than citing the European pharmaceutical regulations (Directive 2001/83/EC), the U.K. government continued to recognize CE-marked products for a limited time.

Regulations 40

Regulations International Production Government 40

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. The last two weeks have seen a number of pledges made to Gavi for the COVAX AMC, bringing the overall amount raised to US$ 2.4 million in direct funding and $6.25

Vaccine 52

Vaccine Government International Virus 52

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. In working together, we envision protecting or enhancing 1 billion lives by 2030.

Government 40

Government Vaccine Production Licensing 40

Agency IQ

DECEMBER 15, 2023

The allowance or “variance” to the prohibition on the open burning of hazardous waste was established at a time when there were no alternatives to the safe treatment of waste explosives. These technical corrections consist of corrections of typos, incorrect regulatory citations, and small oversights.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

JUNE 16, 2023

Amendments to TSCA in 2016 included several new provisions concerning the assertion and Agency review and treatment of CBI claims. The standards would begin with model year 2027 heavy-duty vehicles, with stringency levels through model year 2030 and beyond.

Regulations 40

Regulations Compliance Production Science 40

Codon

FEBRUARY 23, 2025

Because of PEPFAR’s effectiveness, the United Nations (UN) set an ambitious goal in 2022 to end HIV transmission and eliminate AIDS-related deaths by 2030. government issued a limited waiver that let PEPFAR resume HIV treatments abroad, pending further guidance. By February, the U.S.

Clinical Trials 70

Clinical Trials Virus Vaccine DNA 70